Get started
Author

Fátima Postigo-Corrales

Docetaxel Resistance in Breast Cancer: Current Insights and Future Directions
2025 · Fátima Postigo-Corrales, Asunción Beltrán-Videla, et al. · International Journal of Molecular Sciences · 26
PDF
Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al. · Cancer Research · 5
PDF
Discovery of Z1362873773: a novel fascin inhibitor from a large chemical library for colorectal cancer
2025 · Alejandro Rodríguez-Martínez, Lucía Giraldo-Ruiz, et al. · Scientific Reports · 5
PDF
AICAR Stimulates the Pluripotency Transcriptional Complex in Embryonic Stem Cells Mediated by PI3K, GSK3β, and β-Catenin
2020 · Gonzalo Alba, Raquel Martínez, et al. · ACS Omega · 5
Monastrol suppresses invasion and metastasis in human colorectal cancer cells by targeting fascin independent of kinesin-Eg5 pathway
2024 · Begoña Alburquerque-González, Silvia Montoro-García, et al. · Biomedicine & Pharmacotherapy · 4
Pdx1 Is Transcriptionally Regulated by EGR-1 during Nitric Oxide-Induced Endoderm Differentiation of Mouse Embryonic Stem Cells
2022 · Carmen Salguero-Aranda, Amparo Beltran-Povea, et al. · International Journal of Molecular Sciences · 3
Characterizing compounds targeting colorectal cancer derived from monastrol using high-through screening of an extensive combinatorial library
2026 · Alejandro Rodríguez-Martínez, Lucía Giraldo-Ruiz, et al. · Cancer Cell International
Integrative microbiome–methylome analysis links bacterial taxa to colorectal cancer histological subtypes
2026 · Ángel Escudero-Jiménez, Jorge Galán-Ros, et al. · mSystems
PDF
Fascin-Centred Invasive Competence in Eutopic Endometrium: A Hypothesis-Driven Narrative Review of Endometriosis Pathogenesis and Non-Surgical Biomarker Potential
2026 · María Pilar Marín-Sánchez, Daimaris Ortega-Suárez, et al. · International Journal of Molecular Sciences
Supplementary Figure S7 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al.
Figure 5 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al.
Supplementary Figure S3 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al.
Supplementary Figure S2 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al.
Supplementary Figure S4 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al.
Supplementary Figure S11 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al.
Figure 4 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al.
Figure 3 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al.
Figure 6 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al.
Figure 1 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al.
Supplementary Table S3 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al.
Supplementary Table S2 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al.
Figure 2 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al.
Supplementary Figure S5 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al.
Supplementary Table S5 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al.
Supplementary Figure S9 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al.
Works count: 37
Citation count: 48
H-index: 4
I10-index: 1
Year
Topic
Type